Welcome to our dedicated page for Mdxhealth Sa news (Ticker: MDXH), a resource for investors and traders seeking the latest updates and insights on Mdxhealth Sa stock.
MDxHealth SA (NASDAQ: MDXH) is a precision diagnostics company focused on molecular tests for prostate cancer and other urologic diseases. Its news flow centers on financial performance, clinical evidence generation, and corporate developments that shape its position in urologic oncology. The company regularly reports revenue trends, test volumes across tissue-based and liquid-based assays, adjusted EBITDA metrics, and cash balances under International Financial Reporting Standards (IFRS).
Investors following MDXH news will see updates on quarterly and full-year financial results, including revenue growth driven by tests such as Confirm mdx, the Genomic Prostate Score (GPS) test, Select mdx, Resolve mdx, Germline tests, and the ExoDx Prostate (EPI) test acquired with the Exosome Diagnostics business. Releases often discuss the mix between tissue-based and liquid-based testing, gross margins, operating expenses, and progress toward adjusted EBITDA profitability.
MDxHealth’s news also highlights strategic transactions and partnerships. Recent items include the acquisition and integration of the Exosome Diagnostics business from Bio‑Techne, amendments to earnout terms related to the GPS prostate cancer business acquired from Exact Sciences, and collaborations such as the initiation of GPS testing in the UK ProtecT trial in partnership with the University of Oxford. Governance and leadership changes, such as board appointments and finance leadership transitions, are disclosed through press releases furnished on Form 6-K.
This MDXH news page aggregates these company announcements, earnings releases, acquisition updates, and clinical collaboration milestones in one place, helping readers monitor how MDxHealth’s precision diagnostics portfolio, financial profile, and corporate strategy evolve over time.
DLA Piper represented Piper Sandler & Co. and Oppenheimer & Co. as lead book-running managers in the US$45 million IPO of MDxHealth (Nasdaq: MDXH), involving 3,750,000 American Depository Shares (ADSs) priced at US$12.00 each. The offering was structured around 37,500,000 ordinary shares, with an option for underwriters to purchase an additional 562,500 ADSs within 30 days. DLA Piper’s global capital markets team provided comprehensive advisory services for this transaction, enhancing MDxHealth's market presence.